Novonesis Reports 7% Nine-Month Organic Sales Growth, Confirms 2026 Guidance
Novonesis reported 7% organic sales growth for the nine months ended September 30, 2026, and an adjusted EBITDA margin of 37.9%. It confirmed full-year 2026 growth guidance of 7%-8%.
Novonesis announced its financial results for the third quarter and nine months ended September 30, 2026, reporting 7% organic sales growth for the nine-month period. The company achieved an adjusted EBITDA margin of 37.9%. Management confirmed its full-year 2026 growth guidance of 7%-8%. While the company experienced strong growth in its Food & Beverages and Energy segments, this was partially offset by weakness in the North American dietary supplement market.